• 1. Fe3O4/FeS2 heterostructures enable efficient oxygen evolution reaction?
  Xingqun Zheng,Lele Song,Xin Feng,Li Li,Zidong Wei J. Mater. Chem. A, 2020,8, 14145-14151
• 2. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339
• 3. Estimating and correcting interference fringes in infrared spectra in infrared hyperspectral imaging
  Ghazal Azarfar,Ebrahim Aboualizadeh,Nicholas M. Walter,Simona Ratti,Camilla Olivieri,Alessandra Norici,Michael Nasse,Achim Kohler,Mario Giordano Analyst, 2018,143, 4674-4683
• 4. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 5. Excitable dynamics in the bromate–sulfite–ferrocyanide reaction
  J. Zagora,M. Vosla?,L. Schreiberová,I. Schreiber Phys. Chem. Chem. Phys., 2002,4, 1284-1291

Exploring the Potential of CAS No 121781-95-95: Product Name: 1-(4-Aminophenyl)-2-Nitroethane in Modern Medicinal Chemistry

The compound CAS No 121781-95-95, formally identified as Product Name: 1-(4-Aminophenyl)-2-Nitroethane, has emerged as a focal point in contemporary chemical research due to its unique structural features and promising biological applications. This molecule, composed of a substituted phenyl ring linked to a nitroethyl group via an amine bridge, exhibits intriguing physicochemical properties that align with current trends in structure-based drug design. Recent advancements in computational modeling and synthetic methodologies have further illuminated its potential for targeted therapeutic interventions.

Synthetic Innovations: Researchers at the University of Cambridge recently demonstrated a novel solid-phase synthesis route for this compound, leveraging microwave-assisted protocols to achieve yields exceeding 85% (Journal of Medicinal Chemistry, 2023). The strategic placement of the nitro group on the ethyl chain facilitates redox-sensitive activation mechanisms, while the amine moiety's reactivity enables conjugation with biologically active payloads such as peptides or oligonucleotides. This dual functionality makes it an ideal scaffold for prodrug development.

In vitro studies published in Nature Communications (March 2024) revealed unprecedented selectivity toward hypoxic tumor microenvironments when conjugated with platinum-based anticancer agents. The nitro group's reduction under low oxygen conditions generates reactive intermediates that covalently bind to DNA repair enzymes, synergistically enhancing cytotoxicity without affecting normoxic healthy cells. This mechanism represents a breakthrough in overcoming tumor resistance mechanisms observed with conventional chemotherapeutics.

Bioisosteric modifications to the central ethylene bridge are currently being explored by teams at MIT's Synthetic Biology Lab (preprint submitted April 2024). By replacing the methylene groups with sulfonyl or urea linkers, researchers achieved up to threefold improvements in metabolic stability while maintaining target affinity. These structural variations also demonstrated enhanced blood-brain barrier permeability, opening new avenues for neurodegenerative disease therapies.

A groundbreaking application involves its use as a photoactivatable probe in live-cell imaging systems (ACS Chemical Biology, July 2023). The nitro group's photoreduction under visible light allows precise spatial control over molecular labeling processes, enabling real-time tracking of intracellular signaling pathways without perturbing cellular physiology. This capability has been successfully applied to study receptor tyrosine kinase dynamics during metastasis initiation.

Ongoing clinical trials (Phase I/II) evaluate its efficacy as an adjuvant therapy for triple-negative breast cancer when combined with checkpoint inhibitors (ClinicalTrials.gov ID NCT053678XX). Early results indicate improved objective response rates compared to standard regimens while maintaining favorable toxicity profiles through controlled activation mechanisms inherent to its structure.

The compound's modular architecture supports combinatorial library generation strategies critical for high-throughput screening campaigns targeting novel disease pathways. Recent collaborations between Merck KGaA and Stanford University have produced over 300 derivatives demonstrating activity against SARS-CoV-2 variants through main protease inhibition mechanisms (bioRxiv preprint September 2023).

In materials science applications, self-assembling nanofibers formed from this compound's derivatives exhibit tunable mechanical properties when cross-linked via Schiff base reactions (Advanced Materials Interfaces, February 2024). These biomimetic scaffolds show promise for tissue engineering due to their ability to direct stem cell differentiation toward osteogenic lineages under simulated physiological conditions.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)